Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. Autres places de cotation 17:35:15 25/06/2026			Varia. 5j.	Varia. 1 janv.
14 062,00 ^GBX	+1,09%		+6,90%	+1,97%

25/06	Les grandes fusions-acquisitions dans le secteur pharmaceutique et biotechnologique aux États-Unis depuis dix ans	RE
24/06	L’armée américaine rétablit l’obligation du vaccin contre la grippe pour certains personnels après une flambée dans un centre d’entraînement au Texas	RE

Communiqués

24/06	AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care	BU
15/06	AstraZeneca : Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy	PU
15/06	AstraZeneca : Truqap approved in US for prostate cancer	PU
13/06	TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	BU
12/06	AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	PU
08/06	AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio	PU
07/06	CEO of AstraZeneca: “AI is fundamentally changing the way we develop medicines”	AQ
02/06	Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026	AQ
02/06	AstraZeneca - Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial	AQ
02/06	Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial	BU
02/06	AstraZeneca : Presentation (ASCO2026 Presentation 20260601)	PU
02/06	AstraZeneca : Biographies (ASCO2026 biographies 20260601)	PU
01/06	IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial	BU
29/05	AstraZeneca : CARES Phase III clinical programme did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis	PU
29/05	IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer	BU
28/05	AstraZeneca : Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer.	PU
22/05	DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates	BU
22/05	AstraZeneca : Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates	PU
22/05	AstraZeneca : Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours	PU
22/05	AstraZeneca : Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer	PU
22/05	AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026	BU
20/05	Lund University: New study: BMI alone does not fully capture health risks linked to obesity	AQ
18/05	BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension	BU
18/05	AstraZeneca : Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension	PU
18/05	AstraZeneca : Baxfendy approved in the US for hypertension	PU